. Author manuscript; available in PMC: 2019 Oct 1.

Published in final edited form as: Clin Cancer Res. 2018 Jun 5;24(19):4734–4744. doi: 10.1158/1078-0432.CCR-17-1523

Table 1.

Characteristics of extreme phenotype patient subgroups

	Cases	Controls	CALGB 80405 bevacizumab arm	CALGB 80405 total population
Subjects (N)	19	42	899	2334
Female (N, %)	9 (47%)	14 (33%)	364 (40%)	976 (42%)
Age, years (median, range)	59 (31–80)	61 (37–82)	59 (22–85)	59 (21–90)
BMI, kg/m² (median, range)	25.5 (17.7–40.8)	26.9 (18.6–58.4)	26.8 (14.7–70.7)	27.1 (14.5–70.7)
Preexisting diabetes (N, %)	3 (16%)	4 (10%)	139 (15%)	347 (15%)
Preexisting hypertension (N, %)^a	14 (74%)	12 (29%)	361 (40%)	932 (40%)

Difference between cases vs. controls: P = 0.002.